Year: 2026

Share repurchase programme: Transactions of week 13 2026Transaction in Own Shares

Written by Customer Service on March 30, 2026. Posted in Public Companies.

The share repurchase programme runs as from 5 February 2026 and up to and including 29 January 2027 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 3 billion, cf. Corporate Announcement No. 11/2026 of 5 February 2026. The share repurchase programme is initiated and structured in compliance with the Market Abuse Regulation (Regulation (EU) No 596/2014) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions have been made under the program: Number of shares Average purchase price (DKK) Transaction value (DKK)Accumulated, previous announcement 468,013 921.07 431,072,62723 March 2026 17,514 840.88 14,727,22524 March 2026 15,765 845.45 13,328,55725 March 2026 16,302 862.14 14,054,62726...

Virtualware Reports Audited 2025 Results: Margin Improvement and Record Bookings

Written by Customer Service on March 30, 2026. Posted in Earnings Releases And Operating Results.

Gross margin rises to 93.7%, EBITDA reaches €672K (15.53% margin), and the company moves to a pro forma net cash position Bilbao, March 30, 2026.- Virtualware (Euronext Growth Paris: ALVIR) closed 2025 with a gross margin of 93.7%, up from 86.8% in the prior year, and EBITDA of €672,626 (15.53% margin), according to audited annual results filed today with Euronext. The figures confirm the operational picture outlined in the February preliminary communication and show margin improvement, reflecting discipline and resilience throughout the year. Audited revenues reached €4.32 million, in line with the preliminary figure. The EBITDA improvement from the €598,500 (13.8%) reported in the unaudited release reflects the final allocation of depreciation and subsidy recognition under the audited close. The gross margin expansion was driven by the...

Outcome of Subscription to Coop Pank AS Unsecured Subordinated Bonds

Written by Customer Service on March 30, 2026. Posted in Public Companies.

The public offering of Coop Pank AS (hereinafter Coop Pank) unsecured subordinated bonds ended on Friday, 27 March. In the course of the Offering, up to 10,000 unsecured subordinated bonds of Coop Pank with the name of EUR 6,25 Coop Pank bond 26-2037, with the nominal value EUR 1,000 each, the maturity date 1 April 2037 and fixed interest rate of 6,25% per annum, payable quarterly, were offered. Under the terms of the Offering, in case of oversubscription, Coop Pank had the right to increase the volume of the Offering by up to 10,000 additional bonds. The Offering was only carried out in Estonia and not in any other jurisdiction. Altogether 3 853 investors participated in the issue, subscribing orders in the total amount of EUR 57,3 million. This means that the initial issue volume was oversubscribed 5,7 times. Coop Pank used its right...

Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply

Written by Customer Service on March 30, 2026. Posted in Public Companies.

The cobas MPX-E test provides four critical results (for HIV, HCV, HBV, and HEV) in a single test, increasing laboratory efficiency and decreasing healthcare costs. The new test delivers faster turnaround times and allows labs to implement Hepatitis E (HEV) screening without requiring additional instrumentation. This assay is designed for use on the fully automated cobas x800 systems, enabling high-throughput screening with up to 8 hours of walk-away time.Basel, 30 March 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the cobas® MPX-E assay, a qualitative in-vitro test for the detection and discrimination of Human Immunodeficiency Virus (HIV 1 and 2) and Hepatitis C, B, and E viruses, is now available in countries accepting the CE mark. This new assay represents a significant advancement in donor screening by consolidating...

Alkane Executes $110 Million Revolving Credit Facility

Written by Customer Service on March 29, 2026. Posted in Public Companies.

PERTH, Australia, March 29, 2026 (GLOBE NEWSWIRE) — Alkane Resources Limited (ASX: ALK, TSX: ALK, OTCQX: ALKRY) (‘Alkane’) is pleased to announce that it has executed an A$110 million Revolving Credit Facility (“RCF”) and A$40 million Contingent Instrument Facility (“CIF”). Following the early repayment of the $45 million project finance facility in August 20251, and to provide additional flexibility, liquidity, and broaden banking relationships, Alkane executed an A$110 million RCF and A$40 million CIF under a syndicated facilities agreement with Australia and New Zealand Banking Group Limited, Commonwealth Bank of Australia, Macquarie Bank Limited and Westpac Banking Corporation. The RCF may be used for general corporate purposes. The CIF will allow cash used to back performance guarantees to be returned. Alkane is not required...

Autozi Internet Technology (Global) Ltd. Receives NASDAQ Notification Regarding Minimum Market Value of Listed Securities

Written by Customer Service on March 29, 2026. Posted in Public Companies.

BEIJING, March 29, 2026 (GLOBE NEWSWIRE) — Autozi Internet Technology (Global) Ltd. (“Autozi” or the “Company”) (Nasdaq: AZI), one of China’s leading and fastest-growing lifecycle automotive service and supply-chain technology platforms, announced today that it has received a written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated March 25, 2026 indicating that the Company is not in compliance with the minimum Market Value of Listed Securities (“MVLS”) of US$50,000,000 set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq Global Market, as its MVLS for the 30 consecutive business days from February 10, 2026 to March 24, 2026 has failed to meet the minimum requirement. Pursuant to Nasdaq Listing Rule 5810(c)(3)(C), the Company has a compliance period of 180...

Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%

Written by Customer Service on March 29, 2026. Posted in Public Companies.

Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study1 40.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1 Fabhalta granted priority review by FDA for traditional approvalBasel, March 29, 2026 – Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® (iptacopan) in IgA nephropathy (IgAN). Fabhalta demonstrated a statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope, a key marker of kidney function, compared with placebo1. Fabhalta consistently outperformed placebo across key kidney outcomes over two years, demonstrating a slowing of disease progression and the potential to preserve kidney function in IgAN1. The results were published in the New England...

Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity

Written by Customer Service on March 28, 2026. Posted in Public Companies.

In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving clear / almost clear skin Following positive Phase 2 LILAC results, litifilimab is the only investigational program with consistent, positive efficacy results in multiple CLE studies; if approved litifilimab could be the first targeted therapy for this disease CLE is a serious autoimmune disease that impacts the daily lives of patients and can lead to permanent scarring and disfigurementCAMBRIDGE, Mass., March 28, 2026 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) announced positive results from the Phase 2 part of the AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE). Litifilimab...

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

Written by Customer Service on March 28, 2026. Posted in Public Companies.

The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of brepocitinib 30 mg once-daily in dermatomyositis Brepocitinib 30 mg was superior to placebo on the primary and all nine key secondary endpoints, with statistically significant and clinically meaningful improvements observed across measures of global disease activity, muscle strength, skin disease, physical function, and corticosteroid reduction Additional analyses from VALOR, presented at the 2026 American Academy of Dermatology (AAD) Meeting, demonstrated meaningful improvements in itch and skin-related quality of life with brepocitinib 30 mg The U.S. Food and Drug Administration has granted Priority Review to brepocitinib’s New Drug Application (NDA) and assigned a Prescription Drug User Fee Act...

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

Written by Customer Service on March 28, 2026. Posted in Public Companies.

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated with sonelokimab (SLK) achieving HiSCR75 and up to 32% of patients achieving HiSCR100 An analysis of different hallmark lesions of HS shows that up to 25% of patients achieved inflammatory remission at Week 40, defined as a 100% reduction in abscesses (A100), nodules (N100) and draining tunnels (DT100) Patients treated with SLK also showed substantial improvements in HiSQOL items at week 40 versus baseline, ranging from 41% (pain), to 54% (walking, getting dressed) to 62% (down or depressed) Up to 43% of patients achieved an at least 3-point improvement from baseline in the worst skin pain NRS, while 65% of patients achieved an improvement...

Year: 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals